JP2024525567A5 - - Google Patents

Info

Publication number
JP2024525567A5
JP2024525567A5 JP2024500250A JP2024500250A JP2024525567A5 JP 2024525567 A5 JP2024525567 A5 JP 2024525567A5 JP 2024500250 A JP2024500250 A JP 2024500250A JP 2024500250 A JP2024500250 A JP 2024500250A JP 2024525567 A5 JP2024525567 A5 JP 2024525567A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
particles
composition according
metered
formoterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/036542 external-priority patent/WO2023283438A1/en
Publication of JP2024525567A publication Critical patent/JP2024525567A/ja
Publication of JP2024525567A5 publication Critical patent/JP2024525567A5/ja
Pending legal-status Critical Current

Links

JP2024500250A 2021-07-09 2022-07-08 エアロゾル薬物送達のための組成物、方法および系 Pending JP2024525567A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163220362P 2021-07-09 2021-07-09
US63/220,362 2021-07-09
US202163282356P 2021-11-23 2021-11-23
US63/282,356 2021-11-23
PCT/US2022/036542 WO2023283438A1 (en) 2021-07-09 2022-07-08 Compositions, methods and systems for aerosol drug delivery

Publications (2)

Publication Number Publication Date
JP2024525567A JP2024525567A (ja) 2024-07-12
JP2024525567A5 true JP2024525567A5 (https=) 2025-07-15

Family

ID=82748203

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2024500203A Pending JP2024525555A (ja) 2021-07-09 2022-07-08 エアロゾル薬物送達のための組成物、方法および系
JP2024500250A Pending JP2024525567A (ja) 2021-07-09 2022-07-08 エアロゾル薬物送達のための組成物、方法および系
JP2024500201A Pending JP2024527348A (ja) 2021-07-09 2022-07-08 エアロゾル薬物送達のための組成物、方法および系

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2024500203A Pending JP2024525555A (ja) 2021-07-09 2022-07-08 エアロゾル薬物送達のための組成物、方法および系

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024500201A Pending JP2024527348A (ja) 2021-07-09 2022-07-08 エアロゾル薬物送達のための組成物、方法および系

Country Status (28)

Country Link
US (5) US20240252440A1 (https=)
EP (6) EP4393478A3 (https=)
JP (3) JP2024525555A (https=)
KR (3) KR20240042436A (https=)
AU (3) AU2022305962A1 (https=)
CA (3) CA3226557A1 (https=)
CL (3) CL2024000041A1 (https=)
CO (3) CO2024000631A2 (https=)
CR (3) CR20240064A (https=)
DK (3) DK4197528T3 (https=)
DO (3) DOP2024000004A (https=)
EC (1) ECSP24011022A (https=)
ES (3) ES2983201T3 (https=)
FI (3) FI4175620T3 (https=)
HR (3) HRP20240716T1 (https=)
HU (3) HUE067283T2 (https=)
IL (3) IL309888A (https=)
LT (3) LT4175619T (https=)
MA (3) MA60224B1 (https=)
MX (3) MX2024000465A (https=)
PE (3) PE20240807A1 (https=)
PL (3) PL4197528T3 (https=)
PT (3) PT4175619T (https=)
RS (3) RS65598B1 (https=)
SI (3) SI4175620T1 (https=)
SM (3) SMT202400370T1 (https=)
TW (3) TW202317079A (https=)
WO (3) WO2023283439A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250345292A1 (en) * 2022-04-28 2025-11-13 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma
CN116270464B (zh) * 2023-03-01 2025-09-30 深圳市贝美药业有限公司 一种克立硼罗气雾剂及其制备方法
FR3150798B1 (fr) 2023-07-07 2025-11-21 Aptar France Sas Dispositif de distribution de produit fluide
WO2025179277A1 (en) 2024-02-23 2025-08-28 Zelicovich Marcelo Lazaro Aerosol delivery system with enhanced air suspension
TW202600144A (zh) * 2024-02-23 2026-01-01 瑞典商阿斯特捷利康公司 Copd之三重組合療法
WO2026006658A1 (en) * 2024-06-27 2026-01-02 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
US20260007598A1 (en) * 2024-07-05 2026-01-08 Honeywell International Inc. Compositions, devices and methods for respritory delivery of active pharmaceutical ingredients
GB202410910D0 (en) * 2024-07-25 2024-09-11 Bespak Europe Ltd Method of filling a pressurised dispensing container and filled pressurised dispensing container
US12496272B1 (en) 2024-07-31 2025-12-16 Amphastar Pharmaceuticals, Inc. Stable epinephrine suspension formulation for inhalation with HFO propellant
US12383516B1 (en) 2025-01-06 2025-08-12 Amphastar Pharmaceuticals, Inc. Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37872A (en) 1863-03-10 Improved mast-hoop
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (https=) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
ATE287703T1 (de) 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
NZ500555A (en) 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
NZ518401A (en) 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
SI3170880T1 (sl) 2002-10-25 2020-07-31 Honeywell International Inc. Uporaba sestavkov, ki kot hladilni sestavek vsebujejo HFO-1234ZE ali HFO-1234YF
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
ES2335498T3 (es) 2003-03-10 2010-03-29 Nycomed Gmbh Nuevo proceso para la preparacion de reflumilast.
KR20060015316A (ko) 2003-05-28 2006-02-16 넥타르 테라퓨틱스 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
US9308199B2 (en) 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
CN100560598C (zh) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
CA2669924A1 (en) * 2006-11-20 2008-05-29 Cipla Limited An aerosol device
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL3111927T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
SG181870A1 (en) * 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
RU2013155903A (ru) * 2011-05-17 2015-06-27 Перл Терапьютикс, Инк. Композиции, способы и устройства для респираторной доставки двух или более активных средств
CN104080770A (zh) 2011-11-09 2014-10-01 迈兰实验室有限公司 用于制备罗氟司特的改进方法
CN107596518B (zh) * 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
WO2014060464A1 (en) 2012-10-17 2014-04-24 Interquim, S.A. Process for preparing roflumilast
HUE052275T2 (hu) * 2013-01-28 2021-04-28 Incozen Therapeutics Pvt Ltd Eljárások autoimmun, légzõszervi és gyulladásos rendellenességek kezelésére roflumilaszt N-oxid inhalálásával
US20150150787A1 (en) * 2013-05-22 2015-06-04 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
ES2970740T3 (es) 2017-10-09 2024-05-30 Pearl Therapeutics Inc Unidad de administración de aerosol

Similar Documents

Publication Publication Date Title
JP2024525567A5 (https=)
JP2024527348A5 (https=)
JP2024525555A5 (https=)
JP6823118B2 (ja) グリコピロニウム臭化物およびホルモテロールの組合せの安定な加圧
JP6826145B2 (ja) グリコピロニウム臭化物およびホルモテロールの組合せの安定な加圧エアゾール溶液組成物
CN102665679B (zh) 用于copd的联合治疗
CN102665678B (zh) 用于copd的联合治疗
EP2675439A2 (en) Combination of glycopyrrolate and a beta2 -agonist
FI4197528T3 (fi) Koostumuksia, menetelmiä ja järjestelmiä aerosolilääkkeen antamiseen
EP3500241B1 (en) Combination therapy for copd
CN102573791B (zh) 改进的制剂
CN102695496B (zh) 用于copd的气雾剂制剂
US20110182830A1 (en) Inhalation drug products, systems and uses
JP2024545816A5 (https=)
BR102012027127A2 (pt) Composição contida em um inalador farmacêutico pressurizado com medidores de dosagem
HK40005619A (en) Combination therapy for copd
HK40026814B (zh) 格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物
NZ707754B2 (en) Combination of glycopyrrolate and a beta2 -agonist